Selected article for: "antiviral development and immune evasion"
Author: Qian, Wei; Wei, Xiaoqin; Guo, Kelei; Li, Yongtao; Lin, Xian; Zou, Zhong; Zhou, Hongbo; Jin, Meilin
Title: The C-Terminal Effector Domain of Non-Structural Protein 1 of Influenza A Virus Blocks IFN-ß Production by Targeting TNF Receptor-Associated Factor 3
  • Document date: 2017_7_3
    • ID: 00mqmpzw_4
    Snippet: In view of several yet undetermined roles of NS1 in the inhibition of interferon, we conducted a study aimed to determine the importance of the function of the N-and/or C-terminal domains of the NS1 protein in immune evasion. By using the luciferase reporter assay, we were able to demonstrate that the C-terminal ED (AA126 to 225, named NS1/126-225) of the NS1 protein was sufficient to inhibit the production of IFN-β driven by RIG-I(N). Mechanist.....
    Document: In view of several yet undetermined roles of NS1 in the inhibition of interferon, we conducted a study aimed to determine the importance of the function of the N-and/or C-terminal domains of the NS1 protein in immune evasion. By using the luciferase reporter assay, we were able to demonstrate that the C-terminal ED (AA126 to 225, named NS1/126-225) of the NS1 protein was sufficient to inhibit the production of IFN-β driven by RIG-I(N). Mechanistically, NS1/126-225 was found specifically to interact with TRAF3, to dissociate MAVS-TRAF3 complex, and to decrease K63-linked polyubiquitination of TRAF3. This was shown to result in reduced IRF3-dependent production of IFN-β, with subsequent enhancement of virus replication. These data reveal a novel mechanism for how the influenza A virus NS1 protein induces inhibition of the host IFN production and may provide a potential target for antiviral drug development.

    Search related documents:
    Co phrase search for related documents
    • antiviral drug development and immune evasion: 1, 2
    • antiviral drug development and luciferase reporter: 1, 2
    • antiviral drug development and luciferase reporter assay: 1
    • antiviral drug development and novel mechanism: 1
    • antiviral drug development potential target and drug development: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral drug development potential target provide and drug development: 1
    • drug development and IFN β production: 1
    • drug development and IFN production: 1, 2
    • drug development and immune evasion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • drug development and influenza virus NS1 protein: 1
    • drug development and interferon inhibition: 1
    • drug development and luciferase reporter: 1, 2, 3
    • drug development and luciferase reporter assay: 1, 2
    • drug development and novel mechanism: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • drug development and NS1 protein: 1, 2
    • IFN β production and immune evasion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • IFN β production and influenza virus NS1 protein: 1
    • IFN β production and interferon inhibition: 1, 2, 3, 4, 5, 6, 7, 8
    • IFN β production and luciferase reporter: 1, 2, 3, 4, 5, 6, 7